Combination therapy with CD47 blockade and anti-angiogenic drugs produces significant tumor inhibition activity in bladder cancer, which could be explained by the control or normalization of angiogenesis, as well as the further increment of tumor-infiltrating macrophages and pro-inflammatory cytokine production (Figure 6). The gene discussed is CD47; the disease is urinary bladder carcinoma.